The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation

Cell

Volumn 120, Issue 6, 2005, Pages 747-759

  Beuvink, Iwan ^a   Boulay, Anne ^b   Fumagalli, Stefano ^a,c   Zilbermann, Frederic ^a   Ruetz, Stephan ^b   O'Reilly, Terence ^b   Natt, Francois ^b   Hall, Jonathan ^b   Lane, Heidi A ^b   Thomas, George ^a,c  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P21; RAPAMYCIN DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER THERAPY; CELL LINE; DNA DAMAGE; DRUG BINDING; DRUG EFFECT; HALF LIFE TIME; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RNA HYBRIDIZATION; SENSITIZATION; SIDE EFFECT; SOLID TUMOR; TUMOR CELL; WILD TYPE;

EID: 20244365941     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2004.12.040     Document Type: Article

References (57)

1. J. Bartek, and J. Lukas Pathways governing G1/S transition and their response to DNA damage FEBS Lett. 490 2001 117 122
2. J. Bloom, V. Amador, F. Bartolini, G. DeMartino, and M. Pagano Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation Cell 115 2003 71 82
3. A. Boulay, S. Zumstein-Mecker, C. Stephan, I. Beuvink, F. Zilbermann, R. Haller, S. Tobler, C. Heusser, T. O'Reilly, and B. Stolz Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells Cancer Res. 64 2004 252 261
4. M. Cheng, P. Olivier, J.A. Diehl, M. Fero, M.F. Roussel, J.M. Roberts, and C.J. Sherr The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts EMBO J. 18 1999 1571 1583
5. T. Decker, S. Hipp, I. Ringshausen, C. Bogner, M. Oelsner, F. Schneller, and C. Peschel Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin Blood 101 2003 278 285
6. P.B. Dennis, A. Jaeschke, M. Saitoh, B. Fowler, S.C. Kozma, and G. Thomas Mammalian TOR: a homeostatic ATP sensor Science 294 2001 1102 1105
7. J.P. Dutcher Mammalian target of rapamycin (mTOR) inhibitors Curr. Oncol. Rep. 6 2004 111 115
8. W.S. El-Deiry The role of p53 in chemosensitivity and radiosensitivity Oncogene 22 2003 7486 7495
9. W.S. el-Deiry, T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein WAF1, a potential mediator of p53 tumor suppression Cell 75 1993 817 825
10. S. Fan, J.K. Chang, M.L. Smith, D. Duba, A.J. Fornace Jr., and P.M. O'Connor Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard Oncogene 14 1997 2127 2136
11. S. Fan, W.S. el-Deiry, I. Bae, J. Freeman, D. Jondle, K. Bhatia, A.J. Fornace Jr., I. Magrath, K.W. Kohn, and P.M. O'Connor p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents Cancer Res. 54 1994 5824 5830
12. S. Fumagalli, and G. Thomas S6 phosphorylation and signal transduction N. Sonenberg J.W.B. Hershey M.B. Mathews Translational Control of Gene Expression 2000 Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY 695 717
13. A.M. Gaben, C. Saucier, M. Bedin, V. Barbu, and J. Mester Rapamycin inhibits cdk4 activation, p 21(WAF1/CIP1) expression and G1-phase progression in transformed mouse fibroblasts Int. J. Cancer 108 2004 200 206
14. A. Garami, F.J. Zwartkruis, T. Nobukuni, M. Joaquin, M. Roccio, H. Stocker, S.C. Kozma, E. Hafen, J.L. Bos, and G. Thomas Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2 Mol. Cell 11 2003 1457 1466
15. A.L. Gartel, and A.L. Tyner The role of the cyclin-dependent kinase inhibitor p21 in apoptosis Mol. Cancer Ther. 1 2002 639 649
16. J.L.M. Gervais, P. Seth, and H. Zhang Cleavage of CDK inhibitor p21Cip1/Waf1 by caspases is an early event during DNA damage-induced apoptosis J. Biol. Chem. 273 1998 19207 19212
17. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev. 18 2004 1926 1945
18. S. Huang, and P.J. Houghton Targeting mTOR signaling for cancer therapy Curr. Opin. Pharmacol. 3 2003 371 377
19. S. Huang, L.N. Liu, H. Hosoi, M.B. Dilling, T. Shikata, and P.J. Houghton p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin Cancer Res. 61 2001 3373 3381
20. S. Huang, M.A. Bjornsti, and P.J. Houghton Rapamycins: mechanism of action and cellular resistance Cancer Biol. Ther. 2 2003 222 232
21. S. Huang, L. Shu, M.B. Dilling, J. Easton, F.C. Harwood, H. Ichijo, and P.J. Houghton Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1) Mol. Cell 11 2003 1491 1501
22. A. Jaeschke, J. Hartkamp, M. Saitoh, W. Roworth, T. Nobukuni, A. Hodges, J. Sampson, G. Thomas, and R. Lamb Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent J. Cell Biol. 159 2002 217 224
23. A. Jaeschke, P.B. Dennis, and G. Thomas mTOR: a mediator of intracellular homeostasis Curr. Top. Microbiol. Immunol. 279 2004 283 298
24. C.T. Keith, and S.L. Schreiber PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints Science 270 1995 50 51
25. K.K. Khanna, and S.P. Jackson DNA double-strand breaks: signaling, repair and the cancer connection Nat. Genet. 27 2001 247 254
26. M. Kralj, K. Husnjak, T. Korbler, and J. Pavelic Endogenous p21WAF1/CIP1 status predicts the response of human tumor cells to wild-type p53 and p21WAF1/CIP1 overexpression Cancer Gene Ther. 10 2003 457 467
27. J. LaBaer, M.D. Garrett, L.F. Stevenson, J.M. Slingerland, C. Sandhu, H.S. Chou, A. Fattaey, and E. Harlow New functional activities for the p21 family of CDK inhibitors Genes Dev. 11 1997 847 862
28. R. Li, S. Waga, G.J. Hannon, D. Beach, and B. Stillman Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair Nature 371 1994 534 537
29. Z.M. Liu, G.G. Chen, E.K. Ng, W.K. Leung, J.J. Sung, and S.C. Chung Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells Oncogene 23 2004 503 513
30. F.L. Luan, M. Hojo, M. Maluccio, K. Yamaji, and M. Suthanthiran Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy Transplantation 73 2002 1565 1572
31. P.K. Majumder, P.G. Febbo, R. Bikoff, R. Berger, Q. Xue, L.M. McMahon, J. Manola, J. Brugarolas, T.J. McDonnell, and T.R. Golub mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways Nat. Med. 10 2004 594 601
32. S.J. Marygold, and S.J. Leevers Growth signaling: TSC takes its place Curr. Biol. 12 2002 R785 R787
33. F. McCormick Cancer: survival pathways meet their end Nature 428 2004 267 269
34. J.A. Nilsson, and J.L. Cleveland Myc pathways provoking cell suicide and cancer Oncogene 22 2003 9007 9021
35. J. Nourse, E. Firpo, W.M. Flanagan, S. Coats, K. Polyak, M.H. Lee, J. Massague, G.R. Crabtree, and J.M. Roberts Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin Nature 372 1994 570 573
36. T. Owa, H. Yoshino, K. Yoshimatsu, and T. Nagasu Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents Curr. Med. Chem. 8 2001 1487 1503
37. A. Panwalkar, S. Verstovsek, and F.J. Giles Mammalian target of rapamycin inhibition as therapy for hematologic malignancies Cancer 100 2004 657 666
38. -/- mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway Mol. Cell. Biol. 24 2004 3112 3124
39. G.C. Prendergast Signal transduction: Putting translation before transcription Cancer Cell 4 2003 244 245
40. C.G. Proud Role of mTOR signalling in the control of translation initiation and elongation by nutrients Curr. Top. Microbiol. Immunol. 279 2004 215 244
41. V.K. Rajasekhar, A. Viale, N.D. Socci, M. Wiedmann, X. Hu, and E.C. Holland Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes Mol. Cell 12 2003 889 901
42. E. Segal-Bendirdjian, L. Mannone, and A. Jacquemin-Sablon Alteration in p53 pathway and defect in apoptosis contribute independently to cisplatin-resistance Cell Death Differ. 5 1998 390 400
43. J. Seoane, H.V. Le, and J. Massague Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage Nature 419 2002 729 734
44. Y. Shi, L. Frankel, L.G. Radvanyi, L.Z. Penn, R.G. Miller, and G.B. Mills Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro Cancer Res. 55 1995 1982 1988
45. Z. Siddik Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 2003 7265 7279
46. T. Soussi, K. Dehouche, and C. Beroud p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis Hum. Mutat. 15 2000 105 113
47. A. Suzuki, Y. Tsutomi, K. Akahane, T. Araki, and M. Miura Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP Oncogene 17 1998 931 939
48. H. Tian, E.K. Wittmack, and T.J. Jorgensen p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis Cancer Res. 60 2000 679 684
49. K.H. Vousden Switching from life to death: the Miz-ing link between Myc and p53 Cancer Cell 2 2002 351 352
50. K.H. Vousden, and X. Lu Live or let die: the cell's response to p53 Nat. Rev. Cancer 2 2002 594 604
51. R.H. Weiss p21(Waf1/Cip1) as a therapeutic target in breast and other cancers Cancer Cell 4 2003 425 429
52. R.H. Weiss, D. Marshall, L. Howard, A.M. Corbacho, A.T. Cheung, and E.T. Sawai Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21(Waf1/Cip1) Cancer Lett. 189 2003 39 48
53. H.G. Wendel, E. De Stanchina, J.S. Fridman, A. Malina, S. Ray, S. Kogan, C. Cordon-Cardo, J. Pelletier, and S.W. Lowe Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy Nature 428 2004 332 337
54. D.B. Woods, and K.H. Vousden Regulation of p53 Function Exp. Cell Res. 264 2001 56 66
55. S. Wu, C. Cetinkaya, M.J. Munoz-Alonso, N. von der Lehr, F. Bahram, V. Beuger, M. Eilers, J. Leon, and L.G. Larsson Myc represses differentiation- induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter Oncogene 22 2003 351 360
56. Y. Zhang, N. Fujita, and T. Tsuruo Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis Oncogene 18 1999 1131 1138
57. Y. Zhang, X. Gao, L.J. Saucedo, B. Ru, B.A. Edgar, and D. Pan Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins Nat. Cell Biol. 5 2003 578 581